Zeina N. Al-Mahayri

Zeina N. Al-Mahayri

Auto-generated profile, based on publicly available information

Zeina N. Al-Mahayri

Department of Biomedical Sciences, College of Health Sciences, Abu Dhabi University, Al Ain, UAE

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
ADAikaterini Dimopoulou
Aikaterini Dimopoulou
BFBjörn Fischer
Björn Fischer
TGThatjana Gardeitchik
Thatjana Gardeitchik
PSPhillipe Schröter
Phillipe Schröter
HKHülya Kayserili
Hülya Kayserili
UKUwe Kornak
Uwe Kornak

29 June 2021 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
ZAZeina N. Al-Mahayri
Zeina N. Al-Mahayri
MAMohammad Majed Al-Ahmad
Mohammad Majed Al-Ahmad
BABassam R Ali
Bassam R Ali
Introduction: Paclitaxel is a microtubule stabilizer that is currently one of the most utilized chemotherapeutic agents. Its efficacy in breast, uterine, lung and other neoplasms made its safety profile enhancement a subject of great interest. Neurotoxicity is the most common paclitaxel-associated toxicities. In addition, hypersensitivity reactions, hematological, gastrointestinal, and cardiac toxicities are all encountered. Areas covered: The current review explores paclitaxel-induced toxicities mechanisms and risk factors. Studies investigating these toxicities pharmacogenomic biomarkers are reviewed and summarized. There is a limited margin of consistency between the retrieved associations. Variants in genes related to neuro-sensitivity are the most promising candidates for future studies. Expert opinion: Genome-wide association studies highlighted multiple-candidate biomarkers relevant to neuro-sensitivity. Most of the identified paclitaxel-neurotoxicity candidate genes are derived from congenital neuropathy and diabetic-induced neurotoxicity pathways. Future studies should explore these sets of genes while considering the multifactorial nature of paclitaxel-induced neurotoxicity. In the absence of certain paclitaxel-toxicity biomarkers, future research should avoid earlier studies’ caveats. Genes in paclitaxel’s pharmacokinetic pathways could not provide consistent results in any of its associated toxicities. There is a need to dig deeper into toxicity-development mechanisms and personal vulnerability factors, rather than targeting only the genes suspected to affect drug exposure.

15 April 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
ZAZeina N. Al-Mahayri
Zeina N. Al-Mahayri
GPGeorge P. Patrinos
George P. Patrinos
BABassam R Ali
Bassam R Ali
Breast cancer (BC) is one of the most prevalent types of cancer worldwide with high morbidity and mortality rates. Treatment modalities include systemic therapy, in which chemotherapy is a major component in many cases. Several chemotherapeutic agents are used in combinations or as single agents with many adverse events occurring in variable frequencies. These events can be a significant barrier in completing the treatment regimens. Germline genomic variants are thought of as potential determinants in chemotherapy response and the development of side effects. Some pharmacogenomic studies were designed to explore germline variants that can be used as biomarkers for predicting developing toxicity or adverse events during chemotherapy in BC. In this review, we reassess and summarize the major findings of pharmacogenomic studies of chemotherapy toxicity during BC management. In addition, deficiencies hampering utilizing these findings and the potential targets of future research are emphasized. Main insufficiencies in toxicity pharmacogenomics studies originate from study design, sample limitations, heterogeneity of selected genes, variants, and toxicity definitions. With the advent of high throughput genotyping techniques, researchers are expected to explore the identified as well as the potential genetic biomarkers of toxicity and efficacy to improve BC management. However, to achieve this, the limitations of previous work should be evaluated and avoided to reach more conclusive and translatable evidence for personalizing BC chemotherapy.

4 February 2021 in Human Genome Variation
Verified
Journal Article
Open access
PDF file
CRChakkaphan Runcharoen
Chakkaphan Runcharoen
KFKoya Fukunaga
Koya Fukunaga
ISInsee Sensorn
Insee Sensorn
NINareenart Iemwimangsa
Nareenart Iemwimangsa
SKSommon Klumsathian
Sommon Klumsathian
WCWasun Chantratita
Wasun Chantratita
Pharmacogenomics can enhance the outcome of treatment by adopting pharmacogenomic testing to maximize drug efficacy and lower the risk of serious adverse events. Next-generation sequencing (NGS) is a cost-effective technology for genotyping several pharmacogenomic loci at once, thereby increasing publicly available data. A panel of 100 pharmacogenes among Southeast Asian (SEA) populations was resequenced using the NGS platform under the collaboration of the Southeast Asian Pharmacogenomics Research Network (SEAPharm). Here, we present the frequencies of pharmacogenomic variants and the comparison of these pharmacogenomic variants among different SEA populations and other populations used as controls. We investigated the different types of pharmacogenomic variants, especially those that may have a functional impact. Our results provide substantial genetic variations at 100 pharmacogenomic loci among SEA populations that may contribute to interpopulation variability in drug response phenotypes. Correspondingly, this study provides basic information for further pharmacogenomic investigations in SEA populations.

25 April 2013 in Journal of Assisted Reproduction and Genetics
Verified
Journal Article
Closed access
PDF file
MAMarwan Alhalabi
Marwan Alhalabi
MKMazen Kenj
Mazen Kenj
FMFawza Monem
Fawza Monem
ZMZaina Mahayri
Zaina Mahayri
GAGhalia Abou Alchamat
Ghalia Abou Alchamat
AMAmmar Madania
Ammar Madania

4 May 2017 in Pharmacogenomics
Verified
Journal Article
Closed access
ZAZeina N Al-Mahayri
Zeina N Al-Mahayri
GPGeorge P Patrinos
George P Patrinos
BABassam R Ali
Bassam R Ali
Despite the significant advances achieved in pediatric acute lymphocytic leukemia (ALL) treatment, adverse side effects of drugs remain a challenging issue. Numerous ALL pharmacogenomic studies have been conducted to elucidate the predisposing genetic factors for their development. Plausible pharmacogenomic data are available for the osteonecrosis associated with glucocorticoids, the neurotoxicity associated with vincristine and the cardiotoxicity related to anthracyclines. However, these data have not been fully translated into the clinic due to several limitations, most importantly the lack of reliable evidence. The most robust pharmacogenomics data are those for thiopurines and methotrexate use, with evidence-based preemptive testing recommendations for the former. Pharmacogenomics has a significant potential utility in pediatric ALL treatment regimens. In this review, gaps and limitations in this field are emphasized, which may provide a useful guide for future research design.